Taken together, plasma levels of procoagulant agonists, such as fibronectin, or of DNA-histone complexes, may be practical markers to evaluate risk of thrombosis in CRC/MBD patients. The gene discussed is FN1; the disease is Marchiafava-Bignami disease.